Detailed Information

Cited 20 time in webofscience Cited 19 time in scopus
Metadata Downloads

Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Dataopen access

Authors
Kim, Do YoungKim, Hye JinHan, Kwang-HyubHan, Sang YoungHeo, JeongWoo, Hyun YoungUm, Soon HoKim, Yeul HongKweon, Young OhUm, Ho YeongYoon, Jung HwanLee, Wan SikLee, Byung SeokLee, Han ChuRyoo, Baek-YeolYoon, Seung Kew
Issue Date
Oct-2016
Publisher
KOREAN CANCER ASSOCIATION
Keywords
Hepatocellular carcinoma; Sorafenib; Korea
Citation
CANCER RESEARCH AND TREATMENT, v.48, no.4, pp.1243 - 1252
Indexed
SCIE
SCOPUS
KCI
Journal Title
CANCER RESEARCH AND TREATMENT
Volume
48
Number
4
Start Page
1243
End Page
1252
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/6067
DOI
10.4143/crt.2015.278
ISSN
1598-2998
Abstract
Purpose The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study). Materials and Methods Between January 2009 and April 2012, a total of 497 patients were enrolled from 11 sites in Korea. Of these, 482 patients were evaluable for safety analyses. Case report forms of paper or electronic version were used to record safety and efficacy data from all patients. Results More patients of Child-Pugh A received sorafenib for > 8 weeks than did patients of Child Pugh B (55.5% vs. 34.3%). Child-Pugh score did not appear to influence the starting dose of sorafenib, and approximately 70% of patients both in Child-Pugh A and B groups received the recommended initial daily dose of 800 mg (69.0% and 69.5%, respectively). The median overall survival (OS) and time to progression (UP) were 8.5 months and 2.5 months. In Child-Pugh A patients, the median OS and UP were 10.2 months and 2.5 months. The most frequent treatment-emergent drug-related adverse event was hand-foot skin reaction (31.7%), followed by diarrhea (18.0%). The incidence of treatment-emergent adverse events was similar in both Child-Pugh A (85.4%) and Child-Pugh B (84.8%) patients. Conclusion Sorafenib was well tolerated by Korean HCC patients in clinical settings, and the safety profile did not appear to differ by Child-Pugh status. Survival benefit in Korean patients was in line with that of a previous pivotal phase III trial (SHARP).
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Yeul Hong photo

Kim, Yeul Hong
안암병원 (Department of Medical Oncology and Hematology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE